朝聚眼科(02219)于2026年7月7日发布翌日披露报表，披露当日公司在香港联交所场内回购股份共计180,000股，约占回购前公司已发行股本的0.026%。本次回购每股价格介乎2.50港元至2.55港元，总涉资约45.66万港元。
本次回购完成后，因该部分股份尚未被注销，公司已发行股本维持在705,180,500股，且无库存股份变动。公告显示，此次回购依据公司于2026年5月12日通过的购回授权进行，截至当前已累计回购1,237,500股，占该授权通过当日已发行股本的约0.175%，购回授权剩余可购回股份总数为70,518,050股。
公司同时确认，本次股份购回已遵守香港联交所证券上市规则及相关法律法规的要求。公告由执行董事兼联席公司秘书张光弟签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.